InventisBio

InventisBio (Shanghai) Co., Ltd. is an innovative drug research and development enterprise based in China with a global perspective, focusing on major disease areas such as cancer and metabolic diseases. Guided by the concept of addressing unmet clinical needs, the company is committed to developing innovative drugs with independent intellectual property rights, created in China and targeting the global market, persistently providing patients with safer, more effective, and affordable treatment options. InventisBio was co-founded by Dr. Yaolin Wang and several other returned overseas PhDs. The core R&D team averages over 20 years of extensive experience in leading new drug development and team management in multinational pharmaceutical companies. With an in-depth understanding of disease mechanisms, InventisBio selects promising drug targets, designing drugs starting from the binding conformation of compounds and targets, ensuring precision treatment of diseases while maintaining excellent human safety. Based on its outstanding and extensive drug development capabilities and experience, InventisBio has independently developed a series of innovative targeted drugs with patent protection, covering solid tumors such as non-small cell lung cancer, breast cancer, and colorectal cancer, metabolic diseases such as hyperuricemia and gout, as well as autoimmune diseases such as psoriasis.